Key result
AdipoRon ameliorated glomerular endothelial cell and podocyte injury by activating the intracellular Ca2+/LKB1-AMPK/PPARα pathway in models of type 2 diabetes.
Why the study?
Does AdipoRon improve diabetic nephropathy in models of type 2 diabetes?
Does AdipoRon improve diabetic nephropathy in models of type 2 diabetes?
AdipoRon ameliorates diabetic nephropathy and exerts cardioprotective effects in preclinical models of type 2 diabetes by activating the Ca2+/LKB1-AMPK/PPARα pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for AdipoRon in diabetic nephropathy; leaves open translation to human trials.
Adiponectin exerts renoprotective effects against diabetic nephropathy (DN) by activating the AMP-activated protein kinase (AMPK)/peroxisome proliferative-activated receptor– α (PPAR α ) pathway through adiponectin receptors (AdipoRs). AdipoRon is an orally active synthetic adiponectin receptor agonist. We investigated the expression of AdipoRs and the associated intracellular pathways in 27 patients with type 2 diabetes and examined the effects of AdipoRon on DN development in male C57BLKS/J db/db mice, glomerular endothelial cells (GECs), and podocytes. The extent of glomerulosclerosis and tubulointerstitial fibrosis correlated with renal function deterioration in human kidneys. Expression of AdipoR1, AdipoR2, and Ca 2+ /calmodulin-dependent protein kinase kinase– β (CaMKK β ) and numbers of phosphorylated liver kinase B1 (LKB1)– and AMPK-positive cells significantly decreased in the glomeruli of early stage human DN. AdipoRon treatment restored diabetes-induced renal alterations in db/db mice. AdipoRon exerted renoprotective effects by directly activating intrarenal AdipoR1 and AdipoR2, which increased CaMKK β , phosphorylated Ser 431 LKB1, phosphorylated Thr 172 AMPK, and PPAR α expression independently of the systemic effects of adiponectin. AdipoRon-induced improvement in diabetes-induced oxidative stress and inhibition of apoptosis in the kidneys ameliorated relevant intracellular pathways associated with lipid accumulation and endothelial dysfunction. In high-glucose–treated human GECs and murine podocytes, AdipoRon increased intracellular Ca 2+ levels that activated a CaMKK β /phosphorylated Ser 431 LKB1/phosphorylated Thr 172 AMPK/PPAR α pathway and downstream signaling, thus decreasing high-glucose–induced oxidative stress and apoptosis and improving endothelial dysfunction. AdipoRon further produced cardioprotective effects through the same pathway demonstrated in the kidney. Our results show that AdipoRon ameliorates GEC and podocyte injury by activating the intracellular Ca 2+ /LKB1-AMPK/PPAR α pathway, suggesting its efficacy for treating type 2 diabetes–associated DN.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied Type 2 diabetes and diabetic nephropathy (n=27). AdipoRon was evaluated on Renal alterations, oxidative stress, and apoptosis. AdipoRon ameliorated glomerular endothelial cell and podocyte injury by activating the intracellular Ca2+/LKB1-AMPK/PPARα pathway in models of type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: